I’ve got my eye on four trends – the maturation of AI-powered drug development, fierce competition in the GLP-1 space, the ...

The STRIDE trial evaluates the impact of semaglutide ... trading quite close to the 2-year historical minimums. I see that Novo Nordisk is cheaper than its main competitor, Eli Lilly, when ...

At the time, the drugs had sent the two pharma companies to the top of their respective worlds: Novo Nordisk became the ... only hit its stride in 2021, but snack makers were underperforming ...

Glox Therapeutics has appointed of Michael Murray as chair of its board. He will work with the leadership team to accelerate ...

The corporate sector will also be in the spotlight Wednesday, as the quarterly earnings season hits full stride ... results of the previous year. Novo Nordisk (NYSE:NVO) stock rose 1.9% after ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...